Cost–utility analysis of methylphenidate and amphetamine/dexamphetamine in adults with attention‐deficit hyperactivity disorder. Issue 2 (5th March 2017)

• Record Type: Journal Article
• Authors: Shah, Surbhi; Wei, Hongye; Jayawardhana, Jayani; Perri, Matthew; Cobran, Ewan; Young, Henry N.
• Is Part Of: Journal of pharmaceutical health services research. Volume 8:Issue 2(2017:Jun.)
• Page Start: 101
• Page End: 106
• Publication Date: 2017-03-05
• Subjects: amphetamine -- cost–utility -- dexamphetamine -- methylphenidate -- quality of life -- quality‐adjusted life years; Pharmacy -- Research -- Periodicals; Drugs -- Research -- Periodicals; Medical care -- Research -- Periodicals; Public health -- Research -- Periodicals; Pharmaceutical industry -- Periodicals; Health Services Research -- Periodicals; Economics, Pharmaceutical -- Periodicals; 615.1072
• DOI: 10.1111/jphs.12173
• Languages: English
• ISSNs: 1759-8885

Abstract

Abstract: Objectives: Methylphenidate (MPH) and amphetamine/dexamphetamine (AMP/DEX) are the two most common stimulants used to treat attention‐deficit hyperactivity disorder (ADHD). Previous economic evaluations of these treatments mainly focused on children and adolescents. The objective of this study was to conduct a cost–utility analysis of MPH and AMP/DEX treatments in adults with ADHD. Methods: This study was conducted from a third‐party payer perspective using the Medical Expenditure Panel Survey from 2011 to 2013. Patients taking MPH or AMP/DEX were identified from the Prescribed Medicines files. The Short Form‐12 version 2 questionnaire scores were used to calculate quality‐adjusted life years (QALYs). Only direct costs were evaluated from payer's perspective. Incremental cost–utility ratios were calculated, and sensitivity analyses were performed to assess the robustness of the findings at different willingness to pay (WTP) assumptions. Key findings: Of 305 patients, 68.8% were in the AMP/DEX group and 31.2% were in MPH group. The mean annual cost for the MPH group was $4355.31, and the cost for the AMP/DEX group was $6026.40. The mean utilities for MPH and AMP/DEX groups were 0.622 and 0.598 respectively. Sensitivity analyses showed that MPH exceeded AMP/DEX at all WTP values. Conclusion: Methylphenidate was clearly a dominating therapy over AMP/DEX; however, the QALY difference was found to be 0.024. Further research is needed to assess the long‐term impact of using these treatments on various clinical and economic outcomes.